Please use this identifier to cite or link to this item:
Title: Translational pancreatic cancer research: A comparative study on patient-derived xenograft models.
Authors: Rubio-Manzanares Dorado, Mercedes
Marín Gómez, Luis Miguel
Aparicio Sánchez, Daniel
Pereira Arenas, Sheila
Praena-Fernández, Juan Manuel
Borrero Martín, Juan Jose
Farfán López, Francisco
Gómez Bravo, Miguel Ángel
Muntané Relat, Jordi
Padillo Ruiz, Javier
Keywords: Animal model;Immunohistological analysis;Nude mice;Pancreatic cancer;Patient-derived xenograft
metadata.dc.subject.mesh: Adenocarcinoma
Aged, 80 and over
Mice, Nude
Middle Aged
Pancreatic Neoplasms
Prospective Studies
Time Factors
Translational Research, Biomedical
Transplantation, Heterologous
Xenograft Model Antitumor Assays
Issue Date: 2018
Abstract: To assess the viability of orthotopic and heterotopic patient-derived pancreatic cancer xenografts implanted into nude mice. This study presents a prospective experimental analytical follow-up of the development of tumours in mice upon implantation of human pancreatic adenocarcinoma samples. Specimens were obtained surgically from patients with a pathological diagnosis of pancreatic adenocarcinoma. Tumour samples from pancreatic cancer patients were transplanted into nude mice in three different locations (intraperitoneal, subcutaneous and pancreatic). Histological analysis (haematoxylin-eosin and Masson's trichrome staining) and immunohistochemical assessment of apoptosis (TUNEL), proliferation (Ki-67), angiogenesis (CD31) and fibrogenesis (α-SMA) were performed. When a tumour xenograft reached the target size, it was re-implanted in a new nude mouse. Three sequential tumour xenograft generations were generated (F1, F2 and F3). The overall tumour engraftment rate was 61.1%. The subcutaneous model was most effective in terms of tissue growth (69.9%), followed by intraperitoneal (57.6%) and pancreatic (55%) models. Tumour development was faster in the subcutaneous model (17.7 ± 2.6 wk) compared with the pancreatic (23.1 ± 2.3 wk) and intraperitoneal (25.0 ± 2.7 wk) models (P = 0.064). There was a progressive increase in the tumour engraftment rate over successive generations for all three models (F1 28.1% vs F2 71.4% vs F3 80.9%, P In our experience, the faster development and greatest number of viable xenografts could make the subcutaneous model the best option for experimentation in pancreatic cancer.
metadata.dc.identifier.doi: 10.3748/wjg.v24.i7.794
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5807938.pdf2,57 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons